Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Meningococcal vaccines.

Alicia A Price1

  • 1Department of Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, PA 15261, USA. alicia_price@hotmail.com

Current Pharmaceutical Design
|July 14, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Role of Phenolic Nanocompounds in Inflammatory Disorders: Current View and Future Aspects.

Current pharmaceutical design·2026
Same journal

Overcoming Physiological Barriers in Brain Tumor Therapy: Advances in Nanomedicine, Ultramolecular Pharmaceuticals, and Targeted Drug Delivery.

Current pharmaceutical design·2026
Same journal

Breathing Life into Research: The Transformative Potential of Lung-on-a-Chip Technology.

Current pharmaceutical design·2026
Same journal

Cross-Tissue Transcriptome-Wide Association Study Prioritizes Candidate Genes and Compound-Associated Signatures for Osteoarthritis.

Current pharmaceutical design·2026
Same journal

Emerging Role of AI in Gastroenterology and Hepatology: Revolutionizing Medical Device-Assisted Diagnosis.

Current pharmaceutical design·2026
Same journal

Nanostructured Lipid Carriers in Drug Targeting: Characterization, Patents, and Recent Innovations.

Current pharmaceutical design·2026
See all related articles

Neisseria meningitidis causes meningitis worldwide. Developing a vaccine against serogroup B is crucial for global prevention, as current vaccines do not cover all strains.

Area of Science:

  • Microbiology
  • Immunology
  • Vaccinology

Background:

  • Neisseria meningitidis is a primary global cause of meningitis.
  • Meningococcal disease incidence has risen, highlighting the need for improved prevention strategies.
  • Existing vaccines target serogroups A, C, W-135, and Y, but not serogroup B.

Purpose of the Study:

  • To review the biology of Neisseria meningitidis.
  • To discuss current research and vaccine development for meningococcal disease.
  • To evaluate the efficacy of existing Neisseria meningitidis vaccines.

Main Methods:

  • Literature review of Neisseria meningitidis biology.
  • Analysis of current meningococcal vaccine research and development.
  • Discussion of epidemiological trends in meningococcal disease.

Related Experiment Videos

Main Results:

  • Neisseria meningitidis diversity presents challenges for universal vaccine development.
  • A vaccine against serogroup B is essential for comprehensive global meningococcal disease prevention.
  • Current multivalent vaccines offer protection against common serogroups but not all strains.

Conclusions:

  • Effective prevention of global meningococcal disease hinges on the development of a serogroup B vaccine.
  • Continued research into Neisseria meningitidis is vital for advancing vaccine technology.
  • Assessing the efficacy of current vaccines informs future development efforts.